Table 1.
Clinicopathological characteristics of microRNA (miR)‐493 levels in the Fudan University Shanghai Cancer Center cohort of patients with triple‐negative breast cancer
| miR‐493 expression level, n (%) | P‐value, χ2‐test | ||
|---|---|---|---|
| Low | High | ||
| Age, years | .353 | ||
| <40 | 28 (60.9) | 18 (39.1) | ‐ |
| 41‐60 | 197 (70.4) | 83 (29.6) | ‐ |
| >61 | 41 (73.2) | 15 (26.8) | ‐ |
| Menopause | .069 | ||
| No | 129 (65.5) | 68 (34.5) | ‐ |
| Yes | 137 (74.1) | 48 (25.9) | ‐ |
| Grade | .328 | ||
| II | 136 (66.3) | 69 (33.7) | ‐ |
| III | 74 (71.8) | 29 (28.2) | ‐ |
| Tumor size | .746 | ||
| T1 | 125 (69.8) | 54 (30.2) | ‐ |
| T2 | 123 (69.1) | 55 (30.9) | ‐ |
| T3 | 14 (77.8) | 4 (22.2) | ‐ |
| Lymph nodes | .236 | ||
| Negative | 155 (72.1) | 60 (27.9) | ‐ |
| Positive | 111 (66.5) | 56 (33.5) | ‐ |
| ER | .216 | ||
| Negative | 147 (67.1) | 72 (32.9) | ‐ |
| Positive | 119 (73.0) | 44 (27.0) | ‐ |
| PR | .417 | ||
| Negative | 181 (71.0) | 74 (29.0) | ‐ |
| Positive | 85 (66.9) | 42 (33.1) | ‐ |
| HER2 | .707 | ||
| Negative | 150 (70.4) | 63 (29.6) | ‐ |
| Positive | 116 (68.6) | 53 (31.4) | ‐ |
‐, not applicable; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.